Molnupiravir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Molnupiravir (EIDD-2801) 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前体。Molnupiravir 显示出广泛的抗流感病毒 (influenza virus) 和coronaviruses的活性，如 SARS-CoV-2，MERS-CoV，SARS-CoV。Molnupiravir 有用于 COVID-19 和季节性，流行性流感的潜力。

Molnupiravir (EIDD-2801) is an orally bioavailable proagent of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza.

——

Animal Model:C57BL/6 mice (intranasal infection with SARS-CoV)Dosage:50, 150, 500 mg/kg Administration:Oral; every 12 hours for 3 days Result:Body weight loss is significantly diminished or prevented.Animal Model: Ca/09-infected female ferrets Dosage:7 mg/kg Administration:Oral; twice daily for 3.5 days Result:Shed virus load and duration of fever were significantly reduced.

——

Microbiology/Virology

Influenza Virus

Influenza Virus | SARS-CoV

——

——

2492423-29-5

329.31

C13H19N3O7

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 50 mg/mL (151.83 mM; 超声助溶 ) H2O 中的溶解度 : 12.5 mg/mL (37.96 mM; 超声助溶)

CC(C)C(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cc\c(=N/O)[nH]c1=O

——

(-20℃)

With Ice Pack

≥ 2 years